FDA on EC access
This article was originally published in The Tan Sheet
FDA "has never made" the statement that wider access to Plan B could lead to increased promiscuity in women under the age of 16, the agency states in recent letters to members of the House Pro-Choice Caucus. In October, 62 members of the caucus wrote to FDA stating that the agency cited the concern in its May 2004 "not approvable" letter to Barr regarding the firm's switch application. "You attribute to FDA a concern that the agency has never expressed about the proposed Plan B switch to OTC status and we would like to correct the record on this matter at this time," FDA states in a response sent to each signatory of the October letter. The May 6, 2004 memo from CDER Acting Director Steven Galson explaining his decision to find Plan B not approvable notes a lack of studies submitted by the sponsor to address "important potential behavioral changes," including "increased medically risky sexual behavior"...
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
“When COVID-19 hit, we really decided to accelerate plans,” says BlueWillow CEO Dave Peralta. NanoBio Protect contains OTC monograph ingredient benzalkonium chloride in a proprietary nanotechnology, alcohol-free formulation to help reduce germs on skin inside and around the nose that could cause infections.
Eschewing the standard approval mechanisms for COVID-19 vaccines is likely only appropriate in very limited high-risk populations, unless clinical efficacy outcomes are available, former FDA leaders say.